New data on the efficacy of subcutaneous immunotherapies versus intravenous therapies in NSCLC underline not only the benefits for patients but also for healthcare professionals. This is shown by analyses of a phase III study with pembrolizumab sc versus iv.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Psoriasis and PsA
Biologics, oral peptide and trivalent nanobody – current results and trends
- Cancer in Europe: facts and analysis
New Health Policy Report published
- Gastrointestinal complaints
PPI regulation under the microscope
- Chronic pain
Nano-ECS modulator Adezunap improves therapy success
- Wound management: clinical diagnostics
Assessing the risk of infection – from the ABCDE to the TILI score
- Study report
Digital patient education for atrial fibrillation shows measurable effects
- Important basics and studies on cancer and the psyche
Interplay between cancer and mental illness
- IBDmatters - Synergy effects for IBD pathways